These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
25. [Comparison of ifosfamid with cyclophosphamide in the therapy of rat DS carcinosarcoma]. von Ardenne M; Reitnauer PG; Rohde K Arch Geschwulstforsch; 1971; 38(1):15-26. PubMed ID: 4334130 [No Abstract] [Full Text] [Related]
26. Quantitative GLC determination of cyclophosphamide and isophosphamide in biological specimens. Pantarotto C; Bossi A; Belvedere G; Martini A; Donelli MG; Frigerio A J Pharm Sci; 1974 Oct; 63(10):1554-8. PubMed ID: 4436788 [No Abstract] [Full Text] [Related]
27. [Diagnosis and treatment of panarteritis in childhood]. Kühner U; Ackermann R; Frohmüller H Klin Padiatr; 1972 Sep; 184(5):399-408. PubMed ID: 4404493 [No Abstract] [Full Text] [Related]
28. Some novel potential alkylating agents derived from diethylstilbestrol. Roushdi IM; Omar AM; Ragab MS; Awad M J Med Chem; 1976 Nov; 19(11):1333-6. PubMed ID: 1003412 [No Abstract] [Full Text] [Related]
29. Unexpected toxicity in patients treated with iphosphamide. Van Dyk JJ; Falkson HC; Van der Merwe AM; Falkson G Cancer Res; 1972 May; 32(5):921-4. PubMed ID: 4552918 [No Abstract] [Full Text] [Related]
30. Synthesis of new bis(1-aziridinyl) phosphinate alkylating agents containing O-phenyl N-phenylcarbamate side chains. Hsiao YY; Bardos TJ J Med Chem; 1973 Apr; 16(4):391-4. PubMed ID: 4716182 [No Abstract] [Full Text] [Related]
31. Immunosuppressive properties of cyclophosphamide analogues. Harrison EF; Fuquay ME Proc Soc Exp Biol Med; 1972 Mar; 139(3):957-63. PubMed ID: 5063370 [No Abstract] [Full Text] [Related]
32. Potential bis-alkylating agents for cancer chemotherapy. Approaches to the synthesis of 2-sulfonyl-1,4-bis(methanesulfonoxy)butanes. Wilbur JM J Med Chem; 1978 Nov; 21(11):1168-71. PubMed ID: 214556 [TBL] [Abstract][Full Text] [Related]
33. [Experiences with single high dosage iphosphamide therapy in metastasizing malignant neoplasms]. Drings P; Fritsch H Verh Dtsch Ges Inn Med; 1972; 78():166-9. PubMed ID: 4353153 [No Abstract] [Full Text] [Related]
34. New drugs on the horizon in bronchogenic carcinoma. Carter SK Cancer; 1972 Nov; 30(5):1402-9. PubMed ID: 4117256 [No Abstract] [Full Text] [Related]
35. 1,2-bis(arylsulfonyl)hydrazines. 2. The influence of arylsulfonyl and aralkylsulfonyl substituents on antitumor and alkylating activity. Shyam K; Furubayashi R; Hrubiec RT; Cosby LA; Sartorelli AC J Med Chem; 1986 Jul; 29(7):1323-5. PubMed ID: 3806585 [TBL] [Abstract][Full Text] [Related]
36. [Toxicity and antitumor activity of the antibiotic rubomycin and dipin in combination with diuretics (diacarb)]. Stepanova ES Antibiotiki; 1976 Mar; 21(3):262-6. PubMed ID: 946939 [TBL] [Abstract][Full Text] [Related]
37. Potential anticancer agents. 10. Synthesis of N-(4((2,4-diamino-7-pteridyl)methyl)-N10-methylamino)benzoyl)glutamic acid. Suster DC; Feyns VL; Ciustea G; Botez G; Dobre V; Bick R; Niculescu-Duvăz I J Med Chem; 1974 Jul; 17(7):758-60. PubMed ID: 4836410 [No Abstract] [Full Text] [Related]
38. Effect of "3-oxauracil" (2,3-dihydro-1,3-6H-oxazine-dione) in L1210 leukemia. Ujházy V; Reiner P; Farkas J; Skoda J Neoplasma; 1977; 24(3):259-61. PubMed ID: 895936 [TBL] [Abstract][Full Text] [Related]
39. Clinical conference: facial paralysis. Grand rounds. Massachusetts Eye and Ear Infirmary. Schuknecht H; Goodman ML; Weber A; Pappanikou A; Tolpin D Ann Otol Rhinol Laryngol; 1974; 83(2):257-63. PubMed ID: 4817439 [No Abstract] [Full Text] [Related]
40. Mutagenic and chemotherapeutic activity in L1210 leukemia of several monofunctional alkylating agents. Wheeler GP; Adamson DJ; Webster J Cancer Res; 1985 Jul; 45(7):3400-2. PubMed ID: 4005864 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]